Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCORT-NGSK: Switching from Enbrel to Etanercept Biosimilar with Possible Dose Reduction in Rheumatoid Arthritis
jRCTs071190046Completed
- Sponsor
- AYUMI Pharmaceutical Corporation
- Start
- Jun 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by AYUMI Pharmaceutical Corporation. Started Jun 2020; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071190046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190046.